STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] ADC Therapeutics SA SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

ADC Therapeutics SA (ADCT): Oaktree-affiliated entities filed an amended Schedule 13G reporting beneficial ownership of 4.14% of ADCT’s common shares. The filing lists 4,673,441 shares beneficially owned, comprising 4,409,794 common shares and 263,647 shares issuable upon exercise of warrants. The percentage is calculated based on 112,499,395 shares outstanding as of August 1, 2025, increased by the 263,647 warrant shares.

The Oaktree reporting persons disclose shared voting and dispositive power over 4,673,441 shares and certify the securities were not acquired to change or influence control. The Brookfield-related entities named in prior filings now report 0% beneficial ownership and state they are no longer acting together with the Oaktree reporting persons for this position.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of warrants to acquire shares of Common Stock ("Warrants"). The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of Warrants. The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported securities represent 4,409,794 shares of Common Stock and 263,647 shares of Common Stock issuable upon exercise of Warrants. The reported percentage is calculated based on (i) 112,499,395 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025, as increased by (ii) 263,647 Common Stock issuable in respect of the Warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement.


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement.


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement.


SCHEDULE 13G




Comment for Type of Reporting Person: The reporting person which previously reported together with the Oaktree Reporting Persons, has been determined to no longer act together with the Oaktree Reporting Persons, and therefore has ceased to be the beneficial owner of any securities covered by this Statement.


SCHEDULE 13G



Oaktree Fund Administration, LLC
Signature:/s/ Henry Orren
Name/Title:Henry Orren/ Senior Vice President
Date:11/05/2025
Oaktree Capital Holdings, LLC
Signature:/s/ Henry Orren
Name/Title:Henry Orren/ Senior Vice President
Date:11/05/2025
Oaktree Capital Group Holdings GP, LLC
Signature:/s/ Henry Orren
Name/Title:Henry Orren/ Senior Vice President
Date:11/05/2025
Brookfield Asset Management ULC
Signature:/s/ Kathy Sarpash
Name/Title:Kathy Sarpash/Managing Director, Legal & Regulatory
Date:11/05/2025
Brookfield Corporation
Signature:/s/ Swati Mandava
Name/Title:Swati Mandava/ Managing Director, Legal & Regulatory
Date:11/05/2025
Brookfield Asset Management, Ltd.
Signature:/s/ Kathy Sarpash
Name/Title:Kathy Sarpash/ Managing Director, Legal & Regulatory
Date:11/05/2025
BAM Partners Trust
Signature:/s/ Kathy Sarpash
Name/Title:Kathy Sarpash/Secretary
Date:11/05/2025

FAQ

What stake in ADCT did Oaktree report on this Schedule 13G/A?

Oaktree reported 4.14% beneficial ownership of ADC Therapeutics SA common shares.

How many ADCT shares does Oaktree beneficially own?

The filing lists 4,673,441 shares, including 4,409,794 common shares and 263,647 shares issuable upon exercise of warrants.

What share count was used to calculate the 4.14% ownership?

The calculation uses 112,499,395 shares outstanding as of August 1, 2025, plus 263,647 warrant shares.

Do the reporting persons intend to influence control of ADCT?

The certification states the securities were not acquired and are not held to change or influence control.

Do Brookfield-related entities still report ownership in ADCT?

They report 0% beneficial ownership and state they no longer act together with the Oaktree reporting persons for this position.

What type of filing is this for ADCT (ticker: ADCT)?

It is a Schedule 13G/A (Amendment No. 1) reporting beneficial ownership.
Adc Therapeutics Sa

NYSE:ADCT

ADCT Rankings

ADCT Latest News

ADCT Latest SEC Filings

ADCT Stock Data

468.00M
89.16M
19.02%
64.57%
3.68%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
EPALINGES